GT Biopharma Announces Issuance of Two New Patents Covering TriKE® Platform Technologies
GT Biopharma (NASDAQ: GTBP) has been granted two new patents by the USPTO for its TriKE® technology, which targets antigens, including HIV, enhancing the clinical pipeline of therapies. Patent No. 11,098,100 covers TriKE proteins for any antigen, while Patent No. 11,098,101 focuses on HIV antigens. This development secures broad intellectual property rights for the company, supporting its ongoing clinical trials, such as the promising GTB-3550 TriKE® Phase I trial for acute myeloid leukemia and myelodysplastic syndromes, as stated by CEO Anthony Cataldo.
- Issuance of two new patents enhances IP protection for the TriKE® technology platform.
- Positive interim data reported from the GTB-3550 TriKE® Phase I clinical trial.
- None.
BEVERLY HILLS, Calif., Sept. 9, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents:
- Patent No. 11,098,100 – Broad coverage for TriKE proteins targeting any antigen
- Patent No. 11,098,101 – Broad coverage for TriKE proteins targeting HIV antigens
These two patents cover the Company's pipeline of clinical and non-clinical product candidates consisting of tri-specific killer engagers, or TriKEs, designed to target natural killer, or NK, cells and tumor or virus infected cells forming an immune synapse between the NK cell and the tumor cell thereby inducing NK cell activation at that site. The patents broadly include TriKEs that target the CD16 receptor, which includes the more potent camelid nanobody sequence, an IL-15 activating domain and any targeting domain, including but not limited to B7H3, PDL1, CLEC12A, ROR1, CD33, CD133, CD20, CD19, HER2, EpCAM, EGFR, VEGF-A, mesothelin, and HIV.
"2021 has been an exciting year for GT Biopharma as we reported positive, interim data results from our first-in-human GTB-3550 TriKE® Phase I clinical trial for the treatment of refractory/relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As such, we are delighted that these newly granted patents have secured the broad IP rights underpinning the TriKE® technology platform. The granting of these patents provide us the necessary protection to continue to expand our clinical development path forward," noted Anthony Cataldo, Chairman and CEO.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient's immune system's natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements. In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2020, our subsequent current reports on Form 8-K, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and our other filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.
Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans. You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things: (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA's requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control. Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.
We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable. Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Contacts:
Investor Relations:
David Castaneda
David@gtbiopharma.com
414-351-9758
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-biopharma-announces-issuance-of-two-new-patents-covering-trike-platform-technologies-301371999.html
SOURCE GT Biopharma, Inc.
FAQ
What new patents were issued to GT Biopharma on September 9, 2021?
How will the new patents impact GT Biopharma's clinical development?
What is the significance of the GTB-3550 TriKE® Phase I clinical trial results?
What is the relevance of the new patents for GT Biopharma's market position?
